Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.

× No keyword cloud information.

10 in total

1. Decreased striatal dopaminergic innervation in REM sleep behavior disorder.

Authors: R L Albin; R A Koeppe; R D Chervin; F B Consens; K Wernette; K A Frey; M S Aldrich
Journal: Neurology Date: 2000-11-14 Impact factor: 9.910

2. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.

Authors: T S Benamer; J Patterson; D G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H Horstink; H J Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries
Journal: Mov Disord Date: 2000-05 Impact factor: 10.338

3. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group.

Authors:
Journal: Neurology Date: 2000-11-28 Impact factor: 9.910

4. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.

Authors: W Pirker; S Asenbaum; G Bencsits; D Prayer; W Gerschlager; L Deecke; T Brücke
Journal: Mov Disord Date: 2000-11 Impact factor: 10.338

5. Dopa decarboxylase activity of the living human brain.

Authors: A Gjedde; J Reith; S Dyve; G Léger; M Guttman; M Diksic; A Evans; H Kuwabara
Journal: Proc Natl Acad Sci U S A Date: 1991-04-01 Impact factor: 11.205

6. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.

Authors: J Booij; J D Speelman; M W Horstink; E C Wolters
Journal: Eur J Nucl Med Date: 2001-03

7. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

Authors: T Vander Borght; M Kilbourn; T Desmond; D Kuhl; K Frey
Journal: Eur J Pharmacol Date: 1995-12-29 Impact factor: 4.432

8. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.

Authors: K A Frey; R A Koeppe; M R Kilbourn; T M Vander Borght; R L Albin; S Gilman; D E Kuhl
Journal: Ann Neurol Date: 1996-12 Impact factor: 10.422

9. Regulation of dopaminergic activity in early Parkinson's disease.

Authors: J Tedroff; A Ekesbo; E Rydin; B Långström; G Hagberg
Journal: Ann Neurol Date: 1999-09 Impact factor: 10.422

10. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Authors: C S Lee; A Samii; V Sossi; T J Ruth; M Schulzer; J E Holden; J Wudel; P K Pal; R de la Fuente-Fernandez; D B Calne; A J Stoessl
Journal: Ann Neurol Date: 2000-04 Impact factor: 10.422

10 in total

3 in total

Review 1. PET/SPECT imaging agents for neurodegenerative diseases.

Authors: Lin Zhu; Karl Ploessl; Hank F Kung
Journal: Chem Soc Rev Date: 2014-10-07 Impact factor: 54.564

2. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Authors: Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung
Journal: Nucl Med Biol Date: 2007-04 Impact factor: 2.408

3. Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging.

Authors: Deborah Pareto; Albert Cot; Javier Pavía; Carles Falcón; Ignacio Juvells; Francisco Lomeña; Domènec Ros
Journal: Eur J Nucl Med Mol Imaging Date: 2003-07-03 Impact factor: 9.236

3 in total